Prof Marion Subklewe speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about CD33 T cell recruiting antibody constructs for treatment of relapsed refractory AML.
She reports that while they are recruiting patients for ongoing phase I trials, they hope to identify parameters that influence BiTE mediated toxicity and effectivity.
Prof Subklewe discusses the findings from three posters on this topic presented at the meeting and their implications on future research in this area.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.